Accelerated development of vaccine benefit-risk collaboration in Europe (ADVANCE)

01/02/2024
01/02/2024
Network
Download as PDF
Network identification

Network ID

2221111

Network name and Acronym

Accelerated development of vaccine benefit-risk collaboration in Europe (ADVANCE)

Network website

ENCePP partner

No

Institutions that are part of this network

Public Health Evaluation and Projection/Vaccine Safety Evaluation, National Institute for Health and Welfare
Aarhus University & Aarhus University Hospital DEPARTMENT OF CLINICAL EPIDEMIOLOGY
P95 Julius Clinical (former P95 Clinical and Epidemiology Services)

Studies conducted by the network

ADVANCE POC I Benefit-Risk pillar – testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: benefit-risk analysis of pertussis vaccines in pre-school children comparing whole-cell and acellular formulations in the post-marketing setting
ADVANCE POC I Risk pillar - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of safety outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children
ADVANCE POC Study Protocol - Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case. Coverage rates of acellular and whole-cell pertussis-containing vaccines in preschool children (ADVANCE Coverage POC)
ADVANCE Proof-of-Concept study (POC):Testing a system for near real-time monitoring of vaccination coverage, benefits and risks in Europe with acellular pertussis vaccines as test case (ADVANCE POC: monitoring)
Exposure and coverage to routine schedule vaccines in different EU countries (ADVANCE-POC2)
Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of pertussis and pertussis related outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children (benefit study on pertussis vaccination)